1. Introduction {#sec1-cancers-11-01769}
===============

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related deaths globally \[[@B1-cancers-11-01769],[@B2-cancers-11-01769],[@B3-cancers-11-01769],[@B4-cancers-11-01769]\]. Systemic therapy, including molecular target agents, is the main treatment for advanced unresectable HCC \[[@B3-cancers-11-01769],[@B4-cancers-11-01769]\]. In recent years, multiple drugs, such as regorafenib \[[@B5-cancers-11-01769]\], lenvatinib \[[@B6-cancers-11-01769]\], ramucirumab \[[@B7-cancers-11-01769]\], and cabozantinib \[[@B8-cancers-11-01769]\] in addition to sorafenib \[[@B9-cancers-11-01769],[@B10-cancers-11-01769]\], have been shown to be effective for HCC. Of these molecular target agents, sorafenib and lenvatinib are currently available as the first-line treatment for advanced unresectable HCC \[[@B6-cancers-11-01769],[@B9-cancers-11-01769],[@B10-cancers-11-01769]\]. The results of lenvatinib in clinical settings have been recently reported \[[@B11-cancers-11-01769],[@B12-cancers-11-01769]\], and the importance of the relative dose intensity (RDI) has been noted \[[@B13-cancers-11-01769]\]. However, the relationship between dosage and treatment effect in patients with HCC in clinical practice has not fully elucidated and remains unclear. The purpose of this retrospective study was to evaluate the relationship between the RDI and the patients' response to lenvatinib in clinical settings.

2. Materials and Methods {#sec2-cancers-11-01769}
========================

2.1. Patient Characteristics {#sec2dot1-cancers-11-01769}
----------------------------

From March 2018 to May 2019, a total of 93 patients were evaluated who were administrated lenvatinib at the Nagasaki University Hospital and its related facilities. The exclusion criteria for this study were (1) a short observation period (\<2 months, n = 6), (2) absence of proper image analysis (n = 2), and (3) insufficient archival material (n = 4). After the exclusion criteria were applied, data on 81 patients administrated lenvatinib were analyzed retrospectively. HCC was diagnosed based on its typical vascular patterns on either contrast-enhanced computed tomography (CT) or contrast-enhanced magnetic resonance imaging (MRI). Advanced HCC was defined as Barcelona Clinic liver cancer (BCLC) stage C plus stage A/B that was not amenable to curative treatment. Cases that were excluded by REFLECT trial \[[@B6-cancers-11-01769]\], such as patients with ≥50% of their liver occupied by the tumor, obvious invasion of the bile duct, invasion of the main portal vein, and those who had received previous systemic therapy were included in the analysis.

2.2. Treatment Protocol and Relative Dose Intensity {#sec2dot2-cancers-11-01769}
---------------------------------------------------

Lenvatinib (Lenvima^®^; Eisai Co., Ltd., Tokyo, Japan) was orally administered to patients with unresectable HCC. The dose of lenvatinib was set based on body weight and hepatic reserve and was administered at an initial dosage of 12 mg/day for those over 60 kg and 8 mg/day for those under 60 kg. In the case of Child--Pugh grade B, the initial dose was 8 mg. Dose reduction was performed at the discretion of each facility. Lenvatinib continued until disease progression, unacceptable toxicity, or withdrawal of consent.

The RDI was calculated by dividing the actual dose by the ideal dose. The dose intensity was calculated for each week.

2.3. Evaluation Criteria for Adverse Events and Response {#sec2dot3-cancers-11-01769}
--------------------------------------------------------

Dose interruption and sequential reduction of lenvatinib for drug-related adverse events (AEs) were performed according to the guidelines for the administration of lenvatinib. AEs were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.

Treatment response was evaluated by the use of a triphasic scanning technique, CT or MRI, in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) \[[@B14-cancers-11-01769]\] and modified RECIST (mRECIST) \[[@B15-cancers-11-01769]\]. Tumors were evaluated once within the first 8 weeks and then every 8 weeks thereafter. The radiological response was defined as the best response based on the effect assessment after 8 weeks. The objective response (OR) was defined as complete response (CR) plus partial response (PR). Disease control (DC) was defined as OR plus stable disease (SD). The relationship between RDI and response was analyzed using RECIST, which is more objective than mRECIST.

2.4. Ethical Considerations {#sec2dot4-cancers-11-01769}
---------------------------

Informed consent to use medical records was obtained from each patient. These processes and the study protocol were approved by the Ethical Committee of our institution (confirmation number: 19041523-2) in accordance with the Declaration of Helsinki. Our research is available on the Clinical Research Center, Nagasaki University Hospital website (<http://www.mh.nagasaki-u.ac.jp/research/rinsho/patients/open_gastro.html>).

2.5. Statistical Analysis {#sec2dot5-cancers-11-01769}
-------------------------

Continuous variables were dichotomized with respect to the median value. The chi-squared and Fisher's exact tests were used to compare categorical data. A comparison between groups for continuous variables was done by the Student's *t*-test and the Mann--Whitney U test if necessary. The predictive value of the RDI to the radiological response was assessed by receiver operating characteristic curves and calculating the area under the receiver operator curve (AUROC). The optimal cutoff RDI value was determined based on the optimal sensitivity and specificity. Survival curves were assessed by the Kaplan--Meier method. The survival curves were compared using the log-rank test. A *p-*value of 0.05 was considered statistically significant. Data analysis was performed with SPSS version 22.0 (IBM Corp., Armonk, NY, USA).

3. Results {#sec3-cancers-11-01769}
==========

3.1. Patient Characteristics {#sec3dot1-cancers-11-01769}
----------------------------

The baseline characteristics of the 81 patients with HCC (66 men, 15 women) who were included in this study are summarized in [Table 1](#cancers-11-01769-t001){ref-type="table"}. The median age of the patients was 72.0 years. Of the 81 patients, 14 patients were Child--Pugh grade B (17.2%), and 34 patients had extrahepatic spread (41.9%). A total of 14 patients had macroscopic portal vein invasion (17.2%), and 15 patients had undergone other systemic therapy (18.5%) and were not included in the REFLECT study. Regarding the previous systemic chemotherapy, all 15 patients were treated with sorafenib.

3.2. Adverse Events {#sec3dot2-cancers-11-01769}
-------------------

In this study, 97.5% of patients had all-grade AEs, and 43.2% of patients had grade ≥3 AEs ([Table 2](#cancers-11-01769-t002){ref-type="table"}). The incidence of all AE grades of hypertension, fatigue, decreased appetite, hypothyroidism, and proteinuria during the observation period was 61.7%, 58.0%, 56.7%, 51.8%, and 45.6%, respectively. In terms of grade ≥3 AEs, proteinuria and elevated liver enzymes occurred more frequently in our study than in the REFLECT study. A total of 68 patients (83.9%) had dose reduction or withdrawal owing to AEs.

3.3. Response {#sec3dot3-cancers-11-01769}
-------------

According to RECIST 1.1, 3 patients (3.7%) had CR, 11 patients had PR (13.6%), and 38 patients had SD (46.9%). The OR rate was 17.3%, and the DC rate was 64.2% ([Table 3](#cancers-11-01769-t003){ref-type="table"}). [Table 3](#cancers-11-01769-t003){ref-type="table"} also presents the findings of mRECIST. The response, according to the Child--Pugh score and performance status (PS), are summarized in [Table 4](#cancers-11-01769-t004){ref-type="table"}. The OR rate in patients who were Child--Pugh grade A was 20.8%, whereas it was 0.0% in patients who were Child--Pugh grade B. The OR rate in patients with a performance status of 0 was 25.0%, whereas it was 6.0% in patients with a performance status of 1/2.

3.4. Overall Survival {#sec3dot4-cancers-11-01769}
---------------------

The median overall survival (OS) was 11.6 months. The OS was compared in the two groups stratified by radiological response. The OS was significantly better in the OR group (*p* = 0.011) ([Figure 1](#cancers-11-01769-f001){ref-type="fig"}). Further, the OS was divided into two groups stratified by the Child--Pugh score and performance status ([Figure 2](#cancers-11-01769-f002){ref-type="fig"}). The OS was significantly better in the Child--Pugh grade A group (*p* \< 0.001) and in the PS 0 group (*p* \< 0.001).

3.5. Relative Dose Intensity and Radiological Response {#sec3dot5-cancers-11-01769}
------------------------------------------------------

The RDI for each week is shown in [Figure 3](#cancers-11-01769-f003){ref-type="fig"}A. The RDI decreased as the number of weeks passed, and the overall rate was 61.1%. In [Figure 3](#cancers-11-01769-f003){ref-type="fig"}B, the RDI is divided into two groups: patients with and without OR. There was a significant difference in the RDI between the two groups from 8 weeks onwards. The median RDI at week 8 was 67.0%, and when it was divided into two groups with a median of 67.0%, the change in size from the baseline was as shown in [Figure 4](#cancers-11-01769-f004){ref-type="fig"}.

3.6. Predictive Ability of Relative Dose Intensity for Radiological Response {#sec3dot6-cancers-11-01769}
----------------------------------------------------------------------------

We examined the predictive ability of RDI for a radiological response. [Figure 5](#cancers-11-01769-f005){ref-type="fig"} shows the area under the ROC curve (AUROC) for OR prediction by RDI. The AUROC for OR prediction by the 4, 8, 12, and 16-week RDI were 0.666, 0.747, 0.731, and 0.704, respectively. The AUROC increased until 8 weeks and then plateaued. Therefore, we examined whether 8-week RDI is useful for predicting OR achievement. The cutoff values are those giving the highest sum of sensitivity plus specificity. The optimal cutoff values for RDI were 90% (sensitivity 77.6%, specificity 74.4%) to achieve OR.

3.7. Overall Survival Stratified by Relative Dose Intensity {#sec3dot7-cancers-11-01769}
-----------------------------------------------------------

OS was divided into two groups according to an RDI of 67.0%, which was the median value of the 8-week RDI ([Figure 6](#cancers-11-01769-f006){ref-type="fig"}). In the 8-week RDI ≥67.0% group, OS was significantly better than in the 8-week RDI\< 67.0% group (*p* = 0.003). [Table 5](#cancers-11-01769-t005){ref-type="table"} compares the high and low 8-week RDI groups. There was a significant difference in BMI, PS, Child--Pugh grade, BCLC stage, platelet count, prothrombin time, albumin, and dose reduction at administration between the low and high 8-week RDI groups. Child--Pugh grade B and poor PS cases tended to have low RDI ([Figure 7](#cancers-11-01769-f007){ref-type="fig"}).

4. Discussion {#sec4-cancers-11-01769}
=============

Lenvatinib is a tyrosine kinase inhibitor that targets VEGF receptors 1--3, fibroblast growth factor receptors 1--4, PDGFRα, RET, and KIT \[[@B16-cancers-11-01769],[@B17-cancers-11-01769]\]. The phase 3 clinical trial, REFLECT \[[@B6-cancers-11-01769]\], was the first study to show that lenvatinib was non-inferior to sorafenib for OS in patients with advanced HCC. Unlike other cancer types, lenvatinib pharmacokinetics in patients with HCC were affected by body weight, supporting a body weight-based dosing approach \[[@B18-cancers-11-01769],[@B19-cancers-11-01769]\].

In the treatment of thyroid cancer with lenvatinib, control of potential AEs and dose optimization are important \[[@B13-cancers-11-01769]\]. In clinical practice, lenvatinib for HCC treatment is administered to more patients with unfavorable conditions, such as those with poor hepatic reserve or poor PS, than in the REFLECT study. Hence, the lenvatinib dose used often differs from the recommended dose. It is necessary to verify how much lenvatinib is required to achieve efficacy.

Our study showed that the required dose was significantly higher in OR cases. The dose after the first 8 weeks was especially important ([Figure 3](#cancers-11-01769-f003){ref-type="fig"}B). We also examined which week\'s RDI was most useful for predicting the achievement of OR. The AUROC for predicting OR by RDI almost plateaued at 8 weeks ([Figure 5](#cancers-11-01769-f005){ref-type="fig"}). The results suggest that 8-week RDI is an important evaluation point. We demonstrated that a high anti-tumor effect can be expected if the 8-week RDI is sufficient. In addition, if the 8-week RDI is sufficient, an extension of OS can be expected owing to a high anti-tumor effect.

Tyrosine kinase inhibitor dosage and therapeutic effects have been reported in other cancers \[[@B20-cancers-11-01769],[@B21-cancers-11-01769]\]. In the treatment of HCC, a relationship between regorafenib and RDI has been reported \[[@B22-cancers-11-01769]\]. In addition, Takahashi, et al. reported the RDI of lenvatinib in HCC treatment \[[@B23-cancers-11-01769]\]. Their report is consistent with our finding that sufficient RDI is important for therapeutic efficacy. Our results are significant in that they provide evidence that the evaluation period should be 8 weeks ([Figure 3](#cancers-11-01769-f003){ref-type="fig"}; [Figure 5](#cancers-11-01769-f005){ref-type="fig"}), involve a more objective size reduction according to the RECIST criteria ([Figure 4](#cancers-11-01769-f004){ref-type="fig"}), and demonstrate a significant difference in OS stratified by RDI ([Figure 6](#cancers-11-01769-f006){ref-type="fig"}).

In our study, the OR rate of 17.3% and DC rate of 64.2%, according to RECIST, were consistent with the results from the REFLECT trial. In addition, the therapeutic effect varied according to the hepatic reserve. In particular, patients with Child--Pugh grade B did not achieve OR, and their OS was poor. Moreover, even in cases with poor PS, the OR rate, as well as the OS, was low. Child--Pugh grade B and poor PS cases tended to have low RDI ([Figure 7](#cancers-11-01769-f007){ref-type="fig"}). Our results suggest that a low RDI was presumed to affect the therapeutic effect. Therefore, to maintain a sufficient RDI, it is essential to administer lenvatinib to patients with Child--Pugh grade A and PS 0.

One of the limitations of the present study was its retrospective nature. Additionally, in our study, the relationship between DC and RDI was weak. It is unclear whether continuing at a low RDI will contribute to SD and an improved prognosis. A further increase in the number of cases and an extension of the observation period is necessary. In addition, combination therapy involving lenvatinib and other treatments should be considered in the future. Regardless of these limitations, our data are thus the first to demonstrate the relationship between RDI and anti-tumor effects according to the RECIST criteria in a clinical setting.

5. Conclusions {#sec5-cancers-11-01769}
==============

In conclusion, our study revealed that a sufficient RDI is required to achieve OR and that OR extends prognosis. It is strongly recommended that lenvatinib be administered at a sufficient dose for patients in good condition.
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![Overall survival stratified by radiological response according to Response Evaluation Criteria in Solid Tumors (RECIST). Kaplan--Meier curves for OR (objective response) and non-OR. There was a significant difference in OS between the two groups (*p* = 0.011).](cancers-11-01769-g001){#cancers-11-01769-f001}

![Overall survival stratified by (**A**) Child--Pugh grade and (**B**) performance status. (**A**) Kaplan--Meier curves for Child--Pugh grade A and Child--Pugh grade B. There was a significant difference in OS between the two groups (*p* \< 0.001). (**B**) Kaplan--Meier curves for performance status 0 and performance status 1/2. There was a significant difference in OS between the two groups (*p* \< 0.001).](cancers-11-01769-g002){#cancers-11-01769-f002}

![Relative dose intensity (RDI) of lenvatinib (**A**) for all patients and (**B**) stratified by radiological response. (A) RDI for each week. The overall RDI was 61.1%. (B) RDI for each week stratified by objective response (OR; black bars) and non-OR (gray bars). After 8 weeks, the OR group tended to have a significantly higher RDI (*p* \< 0.05).](cancers-11-01769-g003){#cancers-11-01769-f003}

![Response rate stratified by relative dose intensity at 8 weeks. In the 8-week RDI\< 67.0% subgroup (black square), the response rate was +2.8%, +6.2%, +10.1%, and +8.3% at 4, 8, 16, and 24 weeks, respectively. In the 8-week RDI ≥ 67.0% subgroup (black circle), the response rate was −9.9%, −19.7%, −8.5%, and −30.2% at 4, 8, 16, and 24 weeks, respectively. The response rate was significantly different each week (*p* \< 0.05).](cancers-11-01769-g004){#cancers-11-01769-f004}

![Discrimination ability of relative dose intensity for radiological response by the area under the receiver operating curve. Plot of the area under the receiver operator curve (AUROC) identifying radiological response by RDI for each week. Maximum AUROC was 0.747 at 8 weeks.](cancers-11-01769-g005){#cancers-11-01769-f005}

![Overall survival stratified by relative dose intensity at 8 weeks. Kaplan--Meier curves stratified by an 8-week RDI of 67.0%. There was a significant difference in overall survival (OS) between the two groups.](cancers-11-01769-g006){#cancers-11-01769-f006}

![Relative dose intensity of lenvatinib stratified by (**A**) Child--Pugh grade and (**B**) radiological response. (**A**) RDI for each week stratified by Child--Pugh grade A (black bars) and Child--Pugh grade B (gray bars). The Child--Pugh grade A group tended to have significantly higher RDI at 8 weeks (*p* \< 0.05). In the Child--Pugh grade B group, the number of cases at 24 weeks was not available and could not be calculated. (B) RDI for each week stratified by performance status (PS) 0 (black bars) and PS 1/2 (gray bars). The PS 0 group tended to have a significantly higher RDI (*p* \< 0.05).](cancers-11-01769-g007){#cancers-11-01769-f007}

cancers-11-01769-t001_Table 1

###### 

Characteristics of the patients enrolled in the present study.

  Variable                  n = 81              
  ------------------------- ------------------- ---------------------
  Age                       year                72.0 (41--88)
  Gender                    male/female         66/15
  BMI                       kg/m^2^             24.10 (17.5--34.4)
  Performance status        0/1/2               48/28/5
  Child--Pugh grade         A/B                 67/14
  ALBI grade                1/2/3               20/57/4
  Macroscopic PV invasion   Vp3 or Vp4          14 (17.2)
  Extrahepatic spread       \+                  34 (41.9)
  BCLC stage                A/B/C               1/19/61
  Etiology                  HBV/HCV/NBNC        22/26/33
  Platelet count            ×10^4^/μL           12.30 (4.0--38.1)
  PT                        \%                  88.0 (47--128)
  T.bil                     mg/dL               0.90 (0.4--2.6)
  Albumin                   g/dL                3.50 (2.2--4.6)
  ALT                       IU/mL               27.0 (11--198)
  AFP                       ng/ml               68.8 (1.8--23,124)
  DCP                       mAU/ml              484.0 (10--990,474)
  Systemic therapy          naïve/experienced   66/15
  Dose reduction            at administration   32 (39.5)

Data are given as the medians with ranges or numbers with percentages. BMI, body mass index; ALBI, Albumin bilirubin index; BCLC, Barcelona Clinic liver cancer; PV, portal vein; PT, prothrombin; T.bil, total bilirubin; ALT, alanine aminotransferase; AFP, alpha fetoprotein; DCP, Des-gamma-carboxy prothrombin.

cancers-11-01769-t002_Table 2

###### 

Frequency of treatment-emergent adverse events.

  Treatment-Emergent Adverse Events             Any Grade    Grade ≥ 3
  --------------------------------------------- ------------ ------------
  All adverse events                            79 (97.5%)   35 (43.2%)
  Hypertension                                  50 (61.7%)   11 (13.6%)
  Fatigue                                       47 (58.0%)   1 (1.2%)
  Decreased appetite                            46 (56.7%)   3 (3.7%)
  Hypothyroidism                                42 (51.8%)   0 (0.0%)
  Proteinuria                                   37 (45.6%)   7 (8.6%)
  Palmar--plantar erythrodysesthesia syndrome   31 (38.2%)   0 (0.0%)
  Thrombocytopenia                              30 (37.0%)   3 (3.7%)
  Elevated liver enzymes                        25 (30.8%)   6 (7.4%)
  Diarrhea                                      20 (24.6%)   0 (0.0%)
  Weight loss                                   18 (22.2%)   1 (1.2%)
  Dysphonia                                     12 (14.8%)   0 (0.0%)
  edema                                         11 (13.5%)   1 (1.2%)
  Rash                                          5 (6.1%)     0 (0.0%)
  Loss of hair                                  1 (1.2%)     0 (0.0%)

cancers-11-01769-t003_Table 3

###### 

Summary of efficacy measures, according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) and Response Evaluation Criteria in Solid Tumors (RECIST).

  Response Category          Lenvatinib (n = 81)   
  -------------------------- --------------------- ------------
  Complete response (CR)     7 (8.6%)              3(3.7%)
  Partial response (PR)      21 (25.9%)            11 (13.6%)
  Stable disease (SD)        23 (28.4%)            38 (46.9%)
  Progressive disease (PD)   20 (24.7%)            23 (28.4%)
  Unknown or not evaluable   10 (12.3%)            6 (7.4%)
  Objective response (OR)    28 (34.6%)            14 (17.3%)
  Disease control (DC)       51 (63.0%)            52 (64.2%)

cancers-11-01769-t004_Table 4

###### 

Summary of efficacy measures according to RECIST stratified by Child--Pugh grade and performance status.

  Factors                    Child--Pugh Grade   Performance Status                
  -------------------------- ------------------- -------------------- ------------ ------------
  Complete response (CR)     3 (4.4%)            0 (0.0%)             2 (4.2%)     1 (3.0%)
  Partial response (PR)      11 (16.4%)          0 (0.0%)             10 (20.8%)   1 (3.0%)
  Stable disease (SD)        32 (47.7%)          6 (42.9%)            24 (50.0%)   14 (42.4%)
  Progressive disease (PD)   18 (26.8%)          5 (35.7%)            10 (20.8%)   13 (39.3%)
  Unknown or not evaluable   3 (4.4%)            3 (21.4%)            1 (2.1%)     5 (15.1%)
  Objective response (OR)    14 (20.8%)          0 (0.0%)             12 (25.0%)   2 (6.0%)
  Disease control (DC)       46 (68.6%)          6 (42.9%)            36 (75.0%)   16 (48.4%)

cancers-11-01769-t005_Table 5

###### 

Comparison between two groups with relative dose intensity.

  Variable                                    8w-RDI ≥ 67.0%      8w-RDI \< 67.0%      *p*-Value             
  ------------------------------------------- ------------------- -------------------- --------------------- ---------
  Age                                         year                71.0 (46--84)        76.0 (41--88)         0.065
  Gender                                      male/female         37/5                 29/10                 0.111
  BMI                                         kg/m^2^             24.65 (18.6--33.6)   22.15 (17.5--34.4)    0.019
  Performance status                          0/1/2               34/8/0               14/20/5               \<0.001
  Child--Pugh grade                           A/B                 38/4                 29/10                 0.055
  ALBI grade                                  1/2/3               11/31/0              9/26/4                0.103
  Macroscopic PV invasion                     Vp3 or Vp4          7 (16.7)             7 (17.9)              0.878
  Extrahepatic spread                         \+                  16 (38.1)            18 (46.2)             0.462
  BCLC stage                                  A/B/C               1/16/25              0/3/36                0.002
  Etiology                                    HBV/HCV/NBNC        13/12/17             9/14/16               0.669
  Platelet count                              ×10^4^/μL           14.85 (4.6--38.1)    10.60 (4.0--28.0)     0.015
  PT                                          \%                  90.5 (64--128)       84.0 (47--118)        0.013
  T.bil                                       mg/dL               0.90 (0.4--1.8)      1.00 (0.4--2.6)       0.307
  Albumin                                     g/dL                3.70 (2.8--4.6)      3.50 (2.2--4.5)       0.028
  ALT                                         IU/mL               27.5 (11--143)       26.0 (11--198)        0.909
  AFP                                         ng/mL               43.0 (1.8--9926)     140.0 (1.9--23,124)   0.061
  DCP                                         mAU/mL              572.5 (10--78884)    458.0 (11--990,474)   0.609
  Systemic therapy                            naïve/experienced   36/6                 30/9                  0.308
  Dose reduction                              at administration   9 (21.4)             23 (59.0)             \<0.001
  Results given as median (range) or n (%).                                                                  
